The backbone of progress – preclinical studies and innovations with zoledronic acid-Reference-Cited by-同舟云学术

The backbone of progress – preclinical studies and innovations with zoledronic acid

Published:2011-02 Issue: Volume:77 Page:S3-S12
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Green Jonathan R.,Guenther Andreas

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference91 articles.

1. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease;Fleisch;Drugs,1991

2. Osteoclast differentiation and activation;Boyle;Nature,2003

3. Cellular and molecular mechanisms of action of bisphosphonates;Rogers;Cancer,2000

4. Metastasis to bone: causes, consequences and therapeutic opportunities;Mundy;Nat Rev Cancer,2002

5. Bondronat (ibandronate) 2mg and 6mg concentrate for solution for infusion [summary of product characteristics]. Welwyn Garden City, Hertfordshire, United Kingdom: Roche; 2010.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Impact of Obesity, Adipose Tissue, and Tumor Microenvironment on Macrophage Polarization and Metastasis;Biology;2022-02-21

2. Zoledronate upregulates MMP-9 and -13 in rat vascular smooth muscle cells by inducing oxidative stress;Drug Design, Development and Therapy;2016-04

3. Pathophysiology of Metastatic Bone Disease and the Role of the Second Generation of Bisphosphonates: From Basic Science to Medicine;Current Pharmaceutical Design;2016-03-01

4. Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study);PLOS ONE;2015-12-03

5. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo;Clinical & Experimental Metastasis;2015-11-19